Moderna seeks US approval for 94.1% effective vaccine

US

Moderna has said it is filing for regulatory approval in the US, and that its vaccine trials have shown no serious safety concerns.

The US-based company has also said its vaccine was 94.1% effective, with 100% efficacy against severe COVID-19 in its phase three trial.

Efficacy was consistent across age, race and ethnicity, as well as gender, the company has said.

Speaking to Reuters news agency, chief medical officer Dr Tal Zaks said: “We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it.”

Products You May Like

Articles You May Like

Trump Is Personally Threatening Republican Senators Who Oppose Matt Gaetz
Police search for British woman who went missing in Poland over a week ago | UK News
10 Best Boxer Briefs That Don’t Ride Up: Rest Easy in 2024
Post Malone’s 2025 Tour: How to Get Tickets
Thousands of jobs to go at Bosch in latest blow to German car industry | Money News